Telmisartan + Hydrochlorothiazide + Amlodipine Tablets

Therapeutic Indication

Hypertension (high blood pressure)

Cardiovascular risk reduction

Adjunct therapy in patients uncontrolled on dual therapy

Renal protection in hypertensive diabetics

+91 85919 78885

Telmisartan + Hydrochlorothiazide + Amlodipine

Tablet

Triple drug combination of Telmisartan, Amlodipine, and Hydrochlorothiazide is indicated for controlling high blood pressure.
High blood pressure can damage blood vessels in several organs, which could lead sometimes to heart attack, heart or kidney failure, stroke, or blindness. There are usually no symptoms of high blood pressure before damage occurs.

Telmisartan belongs to a group of medicines called angiotensin II receptor antagonists. Angiotensin-II is a substance produced in your body which causes your blood vessels to narrow thus increasing your blood pressure
Hydrochlorothiazide- belongs to a group of medicines called thiazide diuretics, which cause your urine output to increase, leading to a lowering of your blood pressure
Amlodipine- is a calcium channel blocker. It lowers the blood pressure by relaxing the blood vessels

Speciality	Cardiology \| Internal Medicine \| Nephrology
Tags	Antihypertensive \| ARB + CCB + Diuretic \| Cardiovascular
Strength	Telmisartan 40 mg Amlodipine 5 mg Hydrochlorothiazide 12.5 mg
Packing Size	10 Tablets

Check all Tablet Range

Click to know More

Mechanism

Telmisartan: Blocks angiotensin II receptors, preventing vasoconstriction and aldosterone release.
Hydrochlorothiazide: Increases renal excretion of sodium and water, reducing plasma volume and blood pressure.
Amlodipine: Inhibits calcium influx into vascular smooth muscle, causing vasodilation. The combination ensures effective blood pressure control and cardiovascular protection.

Pharmacokinetics

Absorption: Telmisartan ~50% bioavailability; Hydrochlorothiazide well absorbed orally; Amlodipine ~60–65%.
Distribution: All highly protein bound.
Metabolism: Telmisartan minimal hepatic metabolism; Amlodipine via CYP3A4; Hydrochlorothiazide minimally metabolized.
Elimination: Telmisartan mainly fecal; Hydrochlorothiazide renal; Amlodipine renal and fecal.
Half-life: Telmisartan ~24 hrs; Hydrochlorothiazide ~6–15 hrs; Amlodipine ~30–50 hrs.

Side Effects

Dizziness
Peripheral edema
Headache
Fatigue
Electrolyte imbalance (Hydrochlorothiazide)
Rare: Hypotension

Contraindication

Hypersensitivity to Telmisartan, Hydrochlorothiazide, or Amlodipine
Pregnancy (especially 2nd and 3rd trimester)
Severe hepatic impairment
Severe renal impairment
Cardiogenic shock (Amlodipine contraindicated)

Interaction

Other antihypertensives (additive effect)
CYP3A4 inhibitors (increase Amlodipine levels)
NSAIDs (may reduce antihypertensive effect)
Potassium-sparing diuretics (risk of hyperkalemia with Telmisartan)

Warning and Precautions

Use under medical supervision only
Monitor blood pressure and electrolytes regularly
Caution in renal impairment
Consult physician during pregnancy and lactation

Dosage

As directed by the Physician.